Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Lung cancer rehab study aims to pinpoint what really matters for patients

NCT ID NCT07434947

Knowledge-focused Sponsor: University Hospital, Grenoble Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study will enroll 63 people with advanced non-small cell lung cancer whose disease has been stable for at least 6 months. Participants will take part in a 3-month rehabilitation program that includes physical activity. Researchers will measure quality of life, hand grip strength, and a sit-to-stand test to see which outcomes best capture the benefits of rehab. The goal is to identify the most useful measures for future studies comparing different rehabilitation approaches.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
rehabilitation program (physical activity)
What this could lead to
If successful, this study could identify the best way to measure whether rehabilitation helps people with advanced lung cancer feel stronger and have a better quality of life.
What could go wrong
This is a small, early-stage study (63 participants) that is not yet recruiting. It is designed to find the right measurement tools, not to prove that rehabilitation works, so results may not lead to immediate changes in care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 63 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Mar 2026

An estimate. Start dates often move.

Expected to finish

Aug 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study population includes patients with metastatic or locally advanced non-small cell lung cancer whose tumor disease is controlled and who are at least 6 months post-treatment with any anti-tumor therapy. They must have a complaint related to physical activity.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adult patients treated for NSCLC at CHUGA, CHMS, or CHANGE * Locally advanced or metastatic NSCLC * Tumor disease controlled for at least 6 months following any type of anti-tumor treatment * ECOG Performance Status 0 to 2 * Patient reporting functional complaints related to physical activity * Covered by the national health insurance system Exclusion Criteria: * Initial management of the tumor disease started ≥ 2 years ago * Residual toxicity of grade ≥ 2 * Estimated life expectancy less than 6 months (at the discretion of the investigator) * Patient with an absolute contraindication to physical activity at the time of consultation (e.g., unstable angina; acute intercurrent event...) * Subject currently in an exclusion period from another study or participating in an interventional study

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Lung cancer (NSCLC) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

lung cancer lung neoplasm Motor Activity non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Lung cancer (NSCLC)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    3 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • CH Métropole Savoie

    Chambéry, Chambéry, 73 100, France

  • CHU Grenoble Alpes

    Grenoble, 38043, France

  • Centre Hospitalier Annecy Genevois

    Annecy, 74370, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.